Analysis
Iambic Therapeutics filed an amended S-1 on October 8 setting terms for its Nasdaq IPO: 9.375 million shares at $15.00 to $17.00 apiece, according to the filing itself.
At the midpoint, that implies a $150 million raise -- a step up from the original filing Pulse covered on September 21, when the AI-drug-discovery startup had left its share count and price blank and was reported to be targeting roughly $100 million.
J.P. Morgan, Jefferies, BofA Securities and Citigroup are joint book-runners on the deal, which would list on the Nasdaq Global Select Market under the ticker IAM. ARK Investment Management and Duquesne Family Office have both indicated non-binding interest in buying up to $60 million of shares combined at the IPO price.
“ARK Investment Management and Duquesne Family Office have both indicated non-binding interest in buying up to $60 million of shares combined at the IPO price.”
That's a notable anchor commitment for a biotech still well short of profitability: Iambic reported a $77.3 million net loss in 2025 against just $9.4 million in collaboration revenue, underscoring how heavily the company has leaned on pharma partnerships -- including with Nvidia and Qatar-linked backers noted in its original filing -- rather than product revenue to fund its pipeline.
The company plans to use the roughly $135 million in expected net proceeds to push its lead drug candidate, IAM1363, through Phase 1 and into Phase 2 and Phase 3 trials, alongside earlier-stage work on IAM217 and IAM-C1. At the midpoint, the deal implies a roughly $758 million market cap.
What changed since September: Iambic went from a placeholder filing to priced terms with real anchor demand, and the implied deal size grew by roughly 50% from what was originally reported. The offering is still contingent on Nasdaq approving the listing and is expected to price next week.
